Dose Transition Pathways for Continual Reassessment Method
Description
Provides the dose transition pathways (DTP) to project in advance
the doses recommended by a model-based design for subsequent patients (stay,
escalate, deescalate or stop early) using all the accumulated toxicity
information; See Yap et al (2017) . DTP
can be used as a design and an operational tool and can be displayed as a
table or flow diagram. The 'dtpcrm' package also provides the modified
continual reassessment method (CRM) and time-to-event CRM (TITE-CRM) with
added practical considerations to allow stopping early when there is
sufficient evidence that the lowest dose is too toxic and/or there is a
sufficient number of patients dosed at the maximum tolerated dose.